HomeFull speed ahead. Keep track of advancements in every frontier

TheTechno Optimist.

No dispatches yet.

insitro

Machine learning, genetics, stem-cell models

USprivateest. 2018insitro.com (opens insitro.com)Checked 25 Sep

The brief

Analyst view
  • Raised a $400M Series C in Mar 2021; partnered with Bristol Myers Squibb on ALS and Eli Lilly on metabolic disease.
  • Moving liver-targeted gene-silencing drugs for metabolic disease toward trials.
Programs

insitro, one program

Updated 1 Oct 2020
ML-driven target discoveryBuilds huge AI-ready datasets from patient-derived stem cells and population genetics, to link genes to disease and pick drug targets.ResearchNextFirst own drug into trialsUpdated 1 Oct 2020View program →
Research · Proto · Pilot · Deploy · Scaling

Peers

AI drug discovery · 3

Company & funding

1 round · as reported
Raised
$400Mdisclosed private rounds
Last round
Series C15 Mar 2021
HQ
US
Founded
2018
DateRoundAmountPost-moneyLead
15 Mar 2021Series C$400M—CPP Investments

Partners & customers

1 partner

People

Key people
Primer